MAPT and Alzheimer disease: For AD, ASOs that are designed to inhibit MAPT exon 10 inclusion have successfully achieved splicing alteration from toxic 4R to 3R in human tau-expressing mice (Schoch et al, 2016), suggesting important therapeutic potential.